Saturday 17 October 2026
Export DERM’s income statement to Excel — free account
Journey Medical Corporation
DERM Healthcare Drug Manufacturers Specialty & Generic
Journey Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $61.9 million, up 10.2% from fiscal 2024. In the quarter to June 2026, revenue grew 23.3%, EPS grew 93.8%, free cash flow fell 84.1% and total debt rose 1.43%, each against the same quarter a year earlier.
4.97
0.16
−3.12%
Follow DERM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.99 | 3.05 | 1.98 | 2.86 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(74.57) | (30.06) | 44.02 | (112.26) | |
P/B ratio |
6.86 | 5.93 | 4.15 | 6.06 | |
Price to Tangible BV |
0.00 | 44.47 | 29.43 | 29.48 | |
EV/Sales |
3.00 | 3.16 | 1.95 | 2.85 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 111.58 | |
EV/Operating CF |
(45.25) | (15.73) | (18.84) | (25.96) | |
EV/FCF |
(9.40) | (7.13) | (5.82) | (8.65) | |
Quick Ratio |
1.08 | 1.44 | 1.38 | 1.35 | |
Current Ratio |
1.42 | 1.79 | 1.72 | 1.59 | |
Net Debt/EBITDA |
(0.66) | 1.56 | 7.47 | (0.11) | |
Debt/Assets |
29.53% | 26.72% | 27.72% | 25.90% | |
Debt/Equity |
0.97 | 0.79 | 0.82 | 0.79 | |
Asset Turnover |
0.80 | 0.71 | 0.73 | 0.76 | |
Operating CF/Net income |
1.03 | 5.04 | (1.30) | 5.56 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(1.63) | (0.47) | (1.67) | 0.50 | |
Research and Development Expense of Revenue |
1.63% | 0.96% | 0.00% | 0.29% | |
Selling, General and Administrative Expense of Revenue |
68.37% | 61.34% | 63.34% | 58.82% | |
Intangible Assets out of Total Assets |
0.34 | 0.29 | 0.29 | 0.26 | |
Share Based Compensation of Revenue |
10.52% | 11.04% | 6.20% | 7.76% | |
Graham Net Nets |
(0.02) | 0.02 | 0.03 | 0.03 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.92%) | (6.10%) | (7.89%) | (3.11%) | |
Free Cash Flow Yield |
(10.65%) | (14.53%) | (16.95%) | (11.55%) | |
Revenue per Share |
0.71 | 0.66 | 0.58 | 0.67 | |
Operating CF per Share |
(0.10) | (0.26) | 0.11 | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.10) | (0.26) | 0.11 | (0.06) | |
Cash per Share |
1.00 | 0.98 | 1.00 | 0.93 | |
Shareholders Equity per Share |
1.04 | 1.30 | 1.13 | 1.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.04 | 1.30 | 1.13 | 1.17 | |
Free Cash Flow |
(2.38) | (6.28) | 2.91 | (1.73) | |
Working Capital |
16.67 | 29.43 | 27.14 | 27.01 | |
Net Current Asset Value |
(2.91) | 4.14 | 4.26 | 6.54 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
14.33 | 20.01 | 21.51 | 25.95 | |
Average Payables |
14.01 | 12.45 | 11.50 | 10.82 | |
Average Inventory |
11.80 | 12.03 | 10.89 | 10.50 | |
Average Assets |
74.62 | 87.42 | 88.25 | 89.76 | |
Average Common Equity |
18.41 | 25.96 | 26.19 | 25.68 |
Columns are period end dates